Lourd Capital buys $315,246 stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Lourd Capital scooped up 498 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 3,811 shares of Eli Lilly and Co which is valued at $315,246.Eli Lilly and Co makes up approximately 0.09% of Lourd Capital’s portfolio.

Other Hedge Funds, Including , Mckinley Carter Wealth Services reduced its stake in LLY by selling 529 shares or 17.01% in the most recent quarter. The Hedge Fund company now holds 2,581 shares of LLY which is valued at $213,500. Eli Lilly and Co makes up approx 0.11% of Mckinley Carter Wealth Services’s portfolio.Tokio Marine Asset Management Co Ltd boosted its stake in LLY in the latest quarter, The investment management firm added 829 additional shares and now holds a total of 91,695 shares of Eli Lilly and Co which is valued at $7,647,363. Eli Lilly and Co makes up approx 0.76% of Tokio Marine Asset Management Co Ltd’s portfolio. Sunnymeath Asset Management added LLY to its portfolio by purchasing 12,760 company shares during the most recent quarter which is valued at $1,024,373. Eli Lilly and Co makes up approx 1.45% of Sunnymeath Asset Management’s portfolio.Tt International reduced its stake in LLY by selling 12,484 shares or 32.12% in the most recent quarter. The Hedge Fund company now holds 26,379 shares of LLY which is valued at $2,093,437. Eli Lilly and Co makes up approx 0.68% of Tt International’s portfolio.

Eli Lilly and Co closed down -0.3 points or -0.36% at $82.42 with 20,93,793 shares getting traded on Thursday. Post opening the session at $83.02, the shares hit an intraday low of $82.37 and an intraday high of $83.02 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *